Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (23325)	7/17/1998 9:45:00 PM
From: Henry Niman	Read Replies (4) \| Respond to of 32384

Bernie, LGND still has much more technology than they can develop on their own. I expect more deals and more equity positions. Some studies suggest that a single drug costs $300 million to bring it to market . By then end of next year LGND will have 5 drugs on the market and about double that number in the clinic. 15 X $300 million = $4.5 Billion and there are many more in preclinical testing. Those who think that the payment for the development of these drugs will somehow magically appear are either very naive or just not thinking things through.